Clinical Trial Results
Eli Lilly posts results of all Lilly-sponsored phase II, phase III and phase IV clinical trials of Lilly marketed products conducted anywhere in the world that were initiated on or after October 15, 2002. This section links to phase II, phase III and phase IV results posted as CTR Summaries on here and/or as CTR Results Record data tables on ClinicalTrials.gov.
Results are in the ICH-E3 synopsis summary format for trials that completed prior to December 8, 2007.
For the CTR Summaries provided here, study results for a product are located in a single Adobe PDF file that you may browse or search using freely available Adobe Reader software
Results are in the Results Record data table format for trials that completed on or after September 27, 2007.
ClinicalTrials.gov contains a search function. Users can find specific information based on trial parameters such as condition, intervention, location, sponsor, phase, study identifiers, recruitment status, etc.
Once a Lilly unmarketed compound receives marketing authorization, results of Lilly-sponsored clinical trials that completed on or after September 27, 2007 will have results disclosed on ClinicalTrials.gov. In addition, Lilly will also disclose results of Lilly-sponsored clinical trials for compounds whose development has been terminated on or after October 1, 2009. This will include Lilly-sponsored Phase 1 clinical trials in patients that initiated on or after October 1, 2009 and Lilly-sponsored Phase 1 clinical trials in healthy volunteers that initiated on or after October 1, 2010.
Summaries/data tables of clinical study results are intended to report the results of the study that were known at the time of each study's completion. The information contained in these summaries/data tables is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Lilly medicines, nor is it intended to provide a comprehensive analysis of all data currently available regarding a particular drug. In some cases, more current information regarding a drug, including post-hoc analyses and meta-analyses, may be available as part of the general body of scientific knowledge in forms such as manuscripts, abstracts, or posters.
Note that clinical studies on Lilly products may also be sponsored and reported by parties other than Lilly in other clinical trial registries.